Regenerative

Think about health from the cellular unit.

A field where research is advancing. We want to be honest about both its possibilities and its limits.

It all begins with an exam and a consultation.

Treatments

Adipose-Derived Mesenchymal Stem Cell Infusion ¥9,900,000 〜 ¥13,860,000 3-infusion course｜Self-funded care (not covered by public insurance)

Cultivate mesenchymal stem cells from your own fat, then return them to the body via IV drip.

Start with a consultation.

Treatment

Adipose-Derived Mesenchymal Stem Cell Infusion — Cultivate mesenchymal stem cells from your own fat, then return them to the body via IV drip.

Total (approx., tax incl.)

¥9,900,000 〜 ¥13,860,000（3-infusion course）｜Self-funded care (not covered by public insurance)

Main risks & side effects

Reported risks include bruising, swelling or pain at the collection site, fever or allergic reaction during infusion, and, rarely, infection. Results vary between individuals.

Disclosure on unapproved medicines/devices

The processed cell products used in this treatment are unapproved under Japan's Pharmaceuticals and Medical Devices Act.
Cells are the patient's own, cultured at the clinic's partnered cell-processing facility (procurement route).
No domestically approved pharmaceutical with the same composition and performance exists.
No approved equivalent is confirmed in other countries; ask your physician about available safety information.
This treatment is not covered by Japan's Adverse Drug Reaction Relief System.
As a self-funded (jiyu-shinryo) treatment, public health insurance does not apply; the full cost is borne by the patient.

NK Cell Therapy ¥1,320,000 〜 ¥2,310,000 course｜Self-funded care (not covered by public insurance)

Activate your own immune cells outside the body, then return them.

Start with a consultation.

Treatment

NK Cell Therapy — Activate your own immune cells outside the body, then return them.

Total (approx., tax incl.)

¥1,320,000 〜 ¥2,310,000（course）｜Self-funded care (not covered by public insurance)

Main risks & side effects

Reported risks include bruising, swelling or pain at the collection site, fever or allergic reaction during infusion, and, rarely, infection. Results vary between individuals.

Disclosure on unapproved medicines/devices

The processed cell products used in this treatment are unapproved under Japan's Pharmaceuticals and Medical Devices Act.
Cells are the patient's own, cultured at the clinic's partnered cell-processing facility (procurement route).
No domestically approved pharmaceutical with the same composition and performance exists.
No approved equivalent is confirmed in other countries; ask your physician about available safety information.
This treatment is not covered by Japan's Adverse Drug Reaction Relief System.
As a self-funded (jiyu-shinryo) treatment, public health insurance does not apply; the full cost is borne by the patient.

Dendritic Cell Peptide Vaccine (WT-1) ¥2,640,000 3-session course｜Self-funded care (not covered by public insurance)

An immune therapy using WT-1 peptides, aimed at cancer prevention.

Start with a consultation.

Treatment

Dendritic Cell Peptide Vaccine (WT-1) — An immune therapy using WT-1 peptides, aimed at cancer prevention.

Total (approx., tax incl.)

¥2,640,000（3-session course）｜Self-funded care (not covered by public insurance)

Main risks & side effects

Reported risks include bruising, swelling or pain at the collection site, fever or allergic reaction during infusion, and, rarely, infection. Results vary between individuals.

Disclosure on unapproved medicines/devices

The processed cell products used in this treatment are unapproved under Japan's Pharmaceuticals and Medical Devices Act.
Cells are the patient's own, cultured at the clinic's partnered cell-processing facility (procurement route).
No domestically approved pharmaceutical with the same composition and performance exists.
No approved equivalent is confirmed in other countries; ask your physician about available safety information.
This treatment is not covered by Japan's Adverse Drug Reaction Relief System.
As a self-funded (jiyu-shinryo) treatment, public health insurance does not apply; the full cost is borne by the patient.

Activated Autologous Lymphocyte Therapy ¥3,900,000 6-session course｜Self-funded care (not covered by public insurance)

Activate your own lymphocytes, then return them to the body.

Start with a consultation.

Treatment

Activated Autologous Lymphocyte Therapy — Activate your own lymphocytes, then return them to the body.

Total (approx., tax incl.)

¥3,900,000（6-session course）｜Self-funded care (not covered by public insurance)

Main risks & side effects

Reported risks include bruising, swelling or pain at the collection site, fever or allergic reaction during infusion, and, rarely, infection. Results vary between individuals.

Disclosure on unapproved medicines/devices

The processed cell products used in this treatment are unapproved under Japan's Pharmaceuticals and Medical Devices Act.
Cells are the patient's own, cultured at the clinic's partnered cell-processing facility (procurement route).
No domestically approved pharmaceutical with the same composition and performance exists.
No approved equivalent is confirmed in other countries; ask your physician about available safety information.
This treatment is not covered by Japan's Adverse Drug Reaction Relief System.
As a self-funded (jiyu-shinryo) treatment, public health insurance does not apply; the full cost is borne by the patient.

Fees shown as total out-of-pocket cost.

Treatment flow

01
First, a consultation and exam. Share your current state.
02
Run necessary tests to determine suitability.
03
Cultivate the harvested cells in a dedicated facility.
04
Return the cultivated cells to the body via IV drip or injection.
05
Monitor progress regularly and plan the next treatment.

Regenerative Medicine Provision Plan — Provided under a provision plan filed with (and accepted by) the authorities pursuant to the Act on the Safety of Regenerative Medicine. Acceptance of a filing is not governmental approval of efficacy.

Start with a consultation.